Search

everythinglearnresearchcommunity

for

Search:↓

User shared a 1-year update on finasteride, noting thicker hair but mild side effects like reduced libido and mild ED. Considering reducing the dose from 1mg to 0.5mg daily to alleviate side effects.

The conversation discusses the use of TRT, dutasteride, minoxidil, and potentially RU58841 for hair loss. Concerns about the risk of developing Cutis verticis gyrata with minoxidil and TRT are raised.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

The user is seeking advice on the best treatment for male pattern baldness, diffuse thinning, and retrograde alopecia, comparing the effectiveness of finasteride, RU58841, and dutasteride, and considering whether to add minoxidil or switch to dutasteride or combine treatments. They are currently on finasteride and are contemplating if adding RU58841 or switching to dutasteride is better, and also asking about the comparison between pyrilutamide and RU58841.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

The user experienced erectile dysfunction from oral finasteride and is considering alternatives like topical high-dose finasteride, RU58841, topical Latanoprost, and oral Minoxidil. Blood tests showed changes in testosterone and DHT levels, and the endocrinologist advised stopping finasteride.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

Despite using Dutasteride, RU58841, and Minoxidil, hair loss continues due to low testosterone levels from taking 15mg of testosterone weekly, which may not produce enough estrogen. Increasing testosterone dosage and stabilizing hormone levels might help address the issue.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

User 36 years old, receding hairline, tried minoxidil, Nizoral, dermarolling, alfatradiol, revivogen, and spiro cream with limited success. Two dermatologists refused to prescribe finasteride. Others shared experiences and suggested finding a different dermatologist.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

A user experienced mild side effects from 0.5mg finasteride daily, including increased estradiol and minor gynecomastia. They are considering taking a low dose of exemestane to reduce estrogen levels.

The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.

Despite using dutasteride, RU58841, minoxidil, and ketoconazole for years, the user continues to experience severe hair loss and thinning. They seek advice after multiple dermatologists confirmed androgenetic alopecia (AGA) but offered no effective solutions.

The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.

Dutasteride and finasteride have similar risks of sexual dysfunction for treating androgenetic alopecia. Users experience varying side effects, indicating individual differences in drug reactions.

Topical spironolactone 5% is being discussed for its effectiveness in treating hair loss, specifically receding temples. The user is inquiring if it works similarly to finasteride as a testosterone blocker.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The conversation discusses hair loss treatments, specifically the use of anti-androgens like RU58841 and Pyrilutamide, which are expensive in India. Alternatives like spironolactone and concerns about the effectiveness of finasteride and dutasteride are also mentioned.

The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.

A user with diffuse hair loss after taking accutane, which might have triggered genetic predisposition to AGA; their experience taking finasteride and experiencing side effects of increased oil production, increased sex drive, worsening hair texture; they are considering zinc supplementation with finasteride or other treatments such as alfatradiol or spironolactone.

A 20-year-old male currently using topical minoxidil 5% is considering starting finasteride 1mg due to elevated hormone levels. He seeks advice on whether to adjust anything before beginning finasteride.

A user shared their experience of hair loss progression after one year on dutasteride, expressing disappointment with no improvement and considering other treatments like RU58841. Other users offered mixed responses, some seeing no change, others suggesting the hair loss might have been worse without treatment, and discussing the role of testosterone and DHT in hair loss.

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

A user experienced unexpected hormone test results after 7 months on 1mg daily finasteride, noting a decrease in estradiol despite expectations of an increase. Other users suggested that hormone responses can vary and that finasteride might still be effective if DHT levels are within range, while also mentioning factors like circadian rhythm and stress that could impact results.

Cutting a 5 mg finasteride tablet into five equal parts and taking one piece daily is recommended for consistent dosing. This approach provides more stable DHT suppression than taking a full 5 mg tablet every five days.

PCOS female visited doctor for hair loss concerns, prescribed spironolactone and minox 5%. Doctor advised against finasteride or dutasteride, user considering self-medication with dutasteride.